Monopar Therapeutics Annual Net Cash Provided by (Used in) Financing Activities in USD from 2016 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Monopar Therapeutics quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2016 to 2023.
  • Monopar Therapeutics Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2024 was $3.18M, a 295% increase year-over-year.
  • Monopar Therapeutics annual Net Cash Provided by (Used in) Financing Activities for 2023 was $2.03M, a 6067% increase from 2022.
  • Monopar Therapeutics annual Net Cash Provided by (Used in) Financing Activities for 2022 was $32.9K, a 99.7% decline from 2021.
  • Monopar Therapeutics annual Net Cash Provided by (Used in) Financing Activities for 2021 was $10.9M, a 33% increase from 2020.
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $2.03M +$1.99M +6067% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-28
2022 $32.9K -$10.8M -99.7% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-28
2021 $10.9M +$2.7M +33% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-23
2020 $8.18M -$1.17M -12.5% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-24
2019 $9.35M +$9.55M Jan 1, 2019 Dec 31, 2019 10-K 2021-03-25
2018 -$206K -$9.74M -102% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-27
2017 $9.54M +$8.27M +655% Jan 1, 2017 Dec 31, 2017 10-K 2019-02-26
2016 $1.26M Jan 1, 2016 Dec 31, 2016 10-K 2018-03-26
* An asterisk sign (*) next to the value indicates that the value is likely invalid.